Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497142 · ClinicalTrials.gov registry record · Phase 1
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
A Phase 1 study of Surgery and Seizures, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04497142: Completed Phase 1 study of Surgery and Seizures, sponsored by Dana-Farber Cancer Institute.
NCT04497142 is a Phase 1 study of Surgery and Seizures that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 52,852-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04497142, a Phase 1 study of Surgery and Seizures, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: * Electrocorticography * Perampanel (Fycompa)
Primary Outcome
Peritumoral hyperexcitability was measured by intraoperative electrocorticography (ECoG) high frequency oscillation (80-500 Hz) rate over 10 minutes within 1 cm of the contrast-enhancing margin at the time of initial glioma resection.
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Perampanel
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 1 |
What the finished NCT04497142 record still lists
NCT04497142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 52,852-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT04497142 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04497142 about?
NCT04497142 is a clinical study titled "Effect of Perampanel on Peritumoral Hyperexcitability in HGG". The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: * Electrocor...
What is the current status of trial NCT04497142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-11-05. Estimated completion is 2023-05-16.
What conditions does trial NCT04497142 study?
This clinical trial studies the following conditions: Surgery, Seizures, Glioma, Malignant.
What interventions are being tested in trial NCT04497142?
The interventions under investigation include: Standard of Care (DRUG), Perampanel (DRUG).
Who is sponsoring clinical trial NCT04497142?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04497142 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04497142's enrollment target sits among peer trials
12 120th of 120 higher than 1 of 120 other Surgery trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis
RECRUITING · Phase 1
-
Terumo Aortic Global Endovascular Registry
RECRUITING
-
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
RECRUITING · NA
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
RECRUITING · Phase 4
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI